Abstract
AbstractKetamine is an open channel blocker of ionotropic glutamatergic N-Methyl-D-Aspartate (NMDA) receptors. The discovery of its rapid antidepressant effects in patients with depression and treatment-resistant depression fostered novel effective treatments for mood disorders. This discovery not only provided new insight into the neurobiology of mood disorders but also uncovered fundamental synaptic plasticity mechanisms that underlie its treatment. In this review, we discuss key clinical aspects of ketamine’s effect as a rapidly acting antidepressant, synaptic and circuit mechanisms underlying its action, as well as how these novel perspectives in clinical practice and synapse biology form a road map for future studies aimed at more effective treatments for neuropsychiatric disorders.
Funder
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
Department of Veterans Affairs | Office of Academic Affiliations, Department of Veterans Affairs
Yale | YSM | Yale Center for Clinical Investigation, Yale School of Medicine
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism
Publisher
Springer Science and Business Media LLC
Subject
Psychiatry and Mental health,Pharmacology
Reference134 articles.
1. Loomer HP, Saunders JC, Kline NS. A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer. Psychiatr Res Rep. 1957;8:129–41.
2. Crane GE. Iproniazid (marsilid) phosphate, a therapeutic agent for mental disorders and debilitating diseases. Psychiatr Res Rep. 1957;8:142–52.
3. Kuhn R. [Treatment of depressive states with an iminodibenzyl derivative (G 22355)]. Schweizerische medizinische Wochenschr. 1957;87:1135–40.
4. Kuhn R. The discovery of the tricyclic antidepressants and the history of their use in the early years. In: Ban TA, Ray OS, editors. A History of the CINP. Brentwood: Brentwood press; 1996. p. 425–35.
5. Study GBoD. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022;9:137–50.
Cited by
38 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献